- Boehringer Ingelheim GmbH said its experimental hepatitis C oral treatment cleared the virus in as many as 82 percent of patients in a study. (Bloomberg)
- A regimen combining experimental drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) suppressed the hepatitis C virus in most patients four weeks after completing treatment, according to a new study. (NASDAQ)
- A drug interaction study of TMC435 with Bristol-Myers an analyst at Danske Bank, in a note to investors. (Bloomberg)
- Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) said Phase I clinical trial results showed a single dose of the hepatitis C virus treatment IDX719 achieved potent viral load reductions. (Marketwatch)
- A commitment to people with hepatitis C Headquartered in Belgium, Janssen Therapeutics EMEA is committed to the further development and commercialization of its investigational drug TMC435 in the EMEA region. (Yahoo Finance)
- A regimen combining experimental drugs from Gilead Sciences Inc. (NASDAQ:GILD) and Bristol-Myers Squibb Co. (NYSE:BMY) suppressed the hepatitis C virus in most patients four weeks after completing treatment, according to a new study. (Marketwatch)
- Further investigation of GS-7977 in a variety of patient populations and combinations will be important in assessing the drugs potential as part of an all-oral regimen for hepatitis C. (TMCnet)
- Achillion Pharmaceuticals (ACHN) has no FDA approved drugs on the market. Achillion is currently focusing on developing its hepatitis C drug ACH-1625, which is ending Phase 2 clinical trials. (Seekingalpha.com)
- As a result, the replication of the virus is effectively inhibited and the level of Hepatitis C virus is profoundly reduced. (PR Newswire)
Thursday, April 19, 2012
Hepatitis c drug
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment